Global Cancer Biomarkers Market Size, Share, Opportunities And Trends By Type (Protein Biomarkers, Genetic Biomarkers, Others), By Cancer Type (Melanoma, Lung cancer, Thyroid cancer, Kidney cancer, Breast Cancer, Others), By Application (Diagnosis, Drug Discovery and Development, Prognosis, Risk Assessment), By End User (Hospitals and Clinics, Diagnostic Centers), And Geography - Forecasts From 2019 To 2024

The cancer biomarkers market is estimated to grow to US$7,782.098 million in 2024 from US$ 18,764.978 at a high CAGR of 15.80% during the forecast period. Biomarkers are the molecules that indicate normal or abnormal processes taking place in the body. Cancer biomarkers can be DNA, mRNA, proteins, metabolites, or processes such as apoptosis, angiogenesis or proliferation and are extensively used for the early diagnoses of cancer, its prognosis and to predict therapeutic response of the drug. The markers may be produced by the tumor or by the other tissues in response to cancer or associated conditions. Cancer diagnosis includes extensive use of molecular biomarkers as part of routine diagnostic tests.

The cancer biomarker market is expected to show significant growth owing to the rising prevalence of cancer globally. As per the World Cancer Research Fund, there were an estimated 18 million cancer cases around the world in 2018. The increasing use of biomarkers for drug discovery and development will also boost the market for cancer biomarkers during the given forecast period. Governments and private organizations have increased their investment in research in this field. However, the high cost of the diagnosis will hamper the growth of the market. Unfavorable reimbursement policies will also restrain the growth of the cancer biomarker market during the given time frame.

By cancer type, breast cancer is expected to hold a significant market share due to increased awareness of breast cancer diagnosis. By application, diagnosis is projected to hold a significant share due to greater awareness regarding the early diagnosis of cancer. By type, protein biomarkers have greater potential for cancer diagnosis, prognosis and the cost involved is also low.

DRIVERS
• An increasing number of cancer cases around the world
• Increasing use of biomarkers for drug discovery and development
• Extensive research on biomarkers

RESTRAINTS
• The high cost of development and commercialization of biomarkers
• Unfavorable regulatory and reimbursement policies

INDUSTRY UPDATE
• Continuous research and development are taking place in the field of cancer biomarkers. According to data published in Cell Metabolism Journal in March 2018, Australian researchers have found a unique metabolic marker that offers a simple, non-invasive blood test for early detection of lung cancer.
• As per a report published in June 2018 in The American Journal of Pathology, CCN3, a protein secreted into the extracellular matrix between cells can be used as a biomarker that predicts metastasis to bone.

SEGMENTATION

The cancer biomarker market has been analyzed through the following segments:

• By Type
o Protein Biomarkers
o Genetic Biomarkers
o Others

• By Cancer Type
o Melanoma
o Lung cancer
o Thyroid cancer
o Kidney cancer
o Breast Cancer
o Others

• By Application
o Diagnosis
o Drug Discovery and Development
o Prognosis
o Risk Assessment

• By End User
o Hospitals and Clinics
o Diagnostic Centers

• By Geography
o North America
? USA
? Canada
? Mexico

o South America
? Brazil
? Argentina
? Others

• Europe
o Germany
o France
o United Kingdom
o Spain
o Others

• Middle East and Africa
o Saudi Arabia
o Israel
o Others

• Asia Pacific
o China
o Japan
o South Korea
o India
o Others

1. INTRODUCTION
1.1. Market Overview
1.2. Market Definition
1.3. Scope of the Study
1.4. Currency
1.5. Assumptions
1.6. Base, and Forecast Years Timeline
2. RESEARCH METHODOLOGY
2.1. Research Design
2.2. Secondary Sources
3. KEY FINDINGS
4. MARKET DYNAMICS
4.1. Market Segmentation
4.2. Market Drivers
4.3. Market Restraints
4.4. Market Opportunities
4.5. Porter’s Five Forces Analysis
4.5.1. Bargaining Power of Suppliers
4.5.2. Bargaining Power of Buyers
4.5.3. Threat of New Entrants
4.5.4. Threat of Substitutes
4.5.5. Competitive Rivalry in the Industry
4.6. Life Cycle Analysis - Regional Snapshot
4.7. Market Attractiveness
5. CANCER BIOMARKER MARKET BY TYPE
5.1. Protein Biomarkers
5.2. Genetic Biomarker
5.3. Others
6. CANCER BIOMARKER MARKET BY CANCER TYPE
6.1. Melanoma
6.2. Lung cancer
6.3. Thyroid cancer
6.4. Kidney cancer
6.5. Breast Cancer
6.6. Others
7. CANCER BIOMARKER MARKET BY APPLICATIONS
7.1 Diagnosis
7.2 Drug Discovery and Development
7.3 Prognosis
7.4 Risk Assessment
8. CANCER BIOMARKER MARKET BY GEOGRAPHY
8.1. North America
8.1.1. USA
8.1.2. Canada
8.1.3. Mexico
8.2. South America
8.2.1. Brazil
8.2.2. Argentina
8.2.3. Others
8.3. Europe
8.3.1. Germany
8.3.2. France
8.3.3. United Kingdom
8.3.4. Spain
8.3.5. Others
8.4. Middle East and Africa
8.4.1. Saudi Arabia
8.4.2. Israel
8.4.3. Others
8.5. Asia Pacific
8.5.1. China
8.5.2. Japan
8.5.3. South Korea
8.5.4. India
8.5.5. Others
9. COMPETITIVE INTELLIGENCE
9.1. Competitive Benchmarking and Analysis
9.2. Recent Investments and Deals
9.3. Strategies of Key Players
10. COMPANY PROFILES
10.1. Oxford Cancer Biomarkers Ltd
10.2. Janssen Global Services, LLC
10.3. Cynvenio Biosystems, Inc
10.4. Human Longevity Inc
10.5. Abcodia Ltd
10.6. Indivumed GmbH
10.7. Caris Life Sciences
10.8. BCAL Diagnostics
10.9. Cellanyx, LLC
10.10. Cancer Genetics Inc.
LIST OF FIGURES
LIST OF TABLES

Oxford Cancer Biomarkers Ltd
Janssen Global Services, LLC
Cynvenio Biosystems, Inc
Human Longevity Inc
Abcodia Ltd
Indivumed GmbH
Caris Life Sciences
BCAL Diagnostics
Cellanyx, LLC
Cancer Genetics Inc.